DZ2665A1 - Conjugués utiles pour le traitement du cancer de la prostate. - Google Patents

Conjugués utiles pour le traitement du cancer de la prostate.

Info

Publication number
DZ2665A1
DZ2665A1 DZ980275A DZ980275A DZ2665A1 DZ 2665 A1 DZ2665 A1 DZ 2665A1 DZ 980275 A DZ980275 A DZ 980275A DZ 980275 A DZ980275 A DZ 980275A DZ 2665 A1 DZ2665 A1 DZ 2665A1
Authority
DZ
Algeria
Prior art keywords
treatment
prostate cancer
conjugates useful
conjugates
useful
Prior art date
Application number
DZ980275A
Other languages
English (en)
French (fr)
Inventor
Stephen F Brady
Feng Dong-Mei
Victor M Garsky
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9804399.5A external-priority patent/GB9804399D0/en
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Application granted granted Critical
Publication of DZ2665A1 publication Critical patent/DZ2665A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DZ980275A 1997-12-02 1998-11-30 Conjugués utiles pour le traitement du cancer de la prostate. DZ2665A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6711097P 1997-12-02 1997-12-02
GBGB9804399.5A GB9804399D0 (en) 1998-03-02 1998-03-02 Conjugates useful in the treatment of prostate cancer

Publications (1)

Publication Number Publication Date
DZ2665A1 true DZ2665A1 (fr) 2003-03-22

Family

ID=26313204

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ980275A DZ2665A1 (fr) 1997-12-02 1998-11-30 Conjugués utiles pour le traitement du cancer de la prostate.

Country Status (26)

Country Link
US (2) US20060148718A1 (xx)
EP (1) EP1036093A1 (xx)
JP (1) JP2001525337A (xx)
KR (1) KR100580137B1 (xx)
CN (1) CN1181092C (xx)
AR (1) AR016427A1 (xx)
AU (1) AU744652B2 (xx)
BG (1) BG65486B1 (xx)
BR (1) BR9815116A (xx)
CA (1) CA2311615A1 (xx)
DZ (1) DZ2665A1 (xx)
EA (1) EA002745B1 (xx)
EE (1) EE200000333A (xx)
HR (1) HRP20000367A2 (xx)
HU (1) HUP0100350A3 (xx)
ID (1) ID24735A (xx)
IL (1) IL136167A0 (xx)
IS (1) IS5502A (xx)
NO (1) NO20002804L (xx)
NZ (1) NZ504615A (xx)
PE (1) PE20000009A1 (xx)
PL (1) PL197006B1 (xx)
SK (1) SK8282000A3 (xx)
TR (1) TR200002260T2 (xx)
TW (1) TW577897B (xx)
WO (1) WO1999028345A1 (xx)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003518000A (ja) * 1998-12-11 2003-06-03 コールター ファーマシューティカル，インコーポレイティド プロドラッグ化合物およびその調製方法
GB9924759D0 (en) * 1999-10-19 1999-12-22 Merck Sharp & Dohme Process for preparing peptide intermediates
US7842581B2 (en) 2003-03-27 2010-11-30 Samsung Electronics Co., Ltd. Methods of forming metal layers using oxygen gas as a reaction source and methods of fabricating capacitors using such metal layers
ES2768224T3 (es) 2007-08-17 2020-06-22 Purdue Research Foundation Conjugados ligando-enlazador de unión a PSMA y métodos para su uso
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
JP6370785B2 (ja) * 2012-08-15 2018-08-08 ビセン メディカル， インコーポレイテッド 前立腺がんイメージングのための前立腺特異的抗原薬剤およびその使用方法
CA2890190A1 (en) * 2012-11-12 2014-05-15 Redwood Bioscience, Inc. Compounds and methods for producing a conjugate
EA201590783A1 (ru) 2012-11-15 2015-11-30 Эндосайт, Инк. Конъюгаты для доставки лекарственных средств и способы лечения заболеваний, вызванных клетками, экспрессирующими psma
EP2992531B1 (en) 2013-04-30 2019-06-19 Hewlett-Packard Enterprise Development LP Memory access rate
CA2924360C (en) 2013-10-18 2022-04-26 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
AU2021405744A1 (en) 2020-12-22 2023-08-03 Cobiores Nv Compounds comprising a tetrapeptidic moiety
WO2022167664A1 (en) 2021-02-07 2022-08-11 Cobiores Nv Compounds comprising a tetrapeptidic moiety

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4203898A (en) * 1977-08-29 1980-05-20 Eli Lilly And Company Amide derivatives of VLB, leurosidine, leurocristine and related dimeric alkaloids
US4296105A (en) * 1978-08-03 1981-10-20 Institut International De Pathologie Cellulaire Et Moleculaire Derivatives of doxorubicine, their preparation and use
US4719312A (en) * 1978-10-02 1988-01-12 Merck & Co., Inc. Lysosometropic detergent therapeutic agents
US4376765A (en) * 1980-03-31 1983-03-15 Institut International De Pathologie Cellulaire Et Moleculaire Medicaments, their preparation and compositions containing same
US4639456A (en) * 1980-06-10 1987-01-27 Omnichem S.A. Vinblastin-23-oyl amino acid derivatives
ATE64396T1 (de) * 1983-04-29 1991-06-15 Omnichem Sa Konjugierte vinblastin-verbindungen und ihre derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.
FR2546163B1 (fr) * 1983-05-16 1987-10-09 Centre Nat Rech Scient Nouveaux derives acyles hydrosolubles de peptides ou d'amino-acides, leur preparation et leur application
FR2626882B1 (fr) * 1988-02-08 1991-11-08 Ire Celltarg Sa Conjugues de derives de vinca comportant une chaine detergente en position c-3
US5391723A (en) * 1989-05-31 1995-02-21 Neorx Corporation Oligonucleotide conjugates
EP0647450A1 (en) * 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
US5599686A (en) * 1994-06-28 1997-02-04 Merck & Co., Inc. Peptides
US6143864A (en) * 1994-06-28 2000-11-07 Merck & Co., Inc. Peptides
US5866679A (en) * 1994-06-28 1999-02-02 Merck & Co., Inc. Peptides
AU708475B2 (en) * 1995-10-18 1999-08-05 Merck & Co., Inc. Conjugates useful in the treatment of benign prostatic hyperplasia
US5998362A (en) * 1996-09-12 1999-12-07 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
AU715632B2 (en) * 1996-09-12 2000-02-03 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
HRP970566A2 (en) * 1996-10-30 1998-08-31 Jones Deborah Defeo Conjugates useful in the treatment of prostate canser

Also Published As

Publication number Publication date
IL136167A0 (en) 2001-05-20
EA200000603A1 (ru) 2000-12-25
CA2311615A1 (en) 1999-06-10
EA002745B1 (ru) 2002-08-29
US20060148718A1 (en) 2006-07-06
CN1284086A (zh) 2001-02-14
WO1999028345A1 (en) 1999-06-10
NO20002804D0 (no) 2000-05-31
AU744652B2 (en) 2002-02-28
CN1181092C (zh) 2004-12-22
AR016427A1 (es) 2001-07-04
PL197006B1 (pl) 2008-02-29
TW577897B (en) 2004-03-01
TR200002260T2 (tr) 2000-12-21
NZ504615A (en) 2003-05-30
BG104563A (en) 2001-04-30
EP1036093A1 (en) 2000-09-20
HRP20000367A2 (en) 2000-12-31
IS5502A (is) 2000-05-19
NO20002804L (no) 2000-07-21
BG65486B1 (bg) 2008-09-30
HUP0100350A2 (hu) 2001-08-28
US20070021350A1 (en) 2007-01-25
JP2001525337A (ja) 2001-12-11
HUP0100350A3 (en) 2001-09-28
EE200000333A (et) 2001-08-15
PL340768A1 (en) 2001-02-26
KR100580137B1 (ko) 2006-05-16
PE20000009A1 (es) 2000-01-27
KR20010032687A (ko) 2001-04-25
AU1612399A (en) 1999-06-16
BR9815116A (pt) 2000-10-10
SK8282000A3 (en) 2000-11-07
ID24735A (id) 2000-08-03

Similar Documents

Publication Publication Date Title
FR15C0070I2 (fr) Composes heteroaromatiques azotes pour le traitement des maladies de cancer
DZ2333A1 (fr) Conjugues utiles au traitement du cancer de la prostate
FR07C0046I2 (fr) Beta-l-2'-desoxy-nucleosides pour le traitement de l'hepatite b
AU1958897A (en) Egf-genistein conjugates for the treatment of cancer
ITMI990375A1 (it) Trattamento del cancro co epotiloni
TR199800436A3 (tr) Primidin türevlerinin kanserin önlenmesi için kullanilmasi.
PT1187632E (pt) Tratamento com anticorpos anti-erbb2
FR2717848B1 (fr) Panneau pour la réalisation de bassins de rétention.
EP0926955A4 (en) Conjugates useful in the treatment of prostate cancer
CH1143977H1 (fr) 2-Oxy-benzoxazine-4-ones destinees au traitement de l'obesite
DZ3014A1 (fr) Médicaments pour le traitement de l'hypertension.
DZ2665A1 (fr) Conjugués utiles pour le traitement du cancer de la prostate.
IS5035A (is) Aðferðir til varnar gegn brjóstakrabbameini
DK0972024T3 (da) Tumorsuppressor designeret TS10Q23.3
ITTO940748A0 (it) Condotto protesico particolarmente per il trattamento di patologie cardiovascolari.
DZ2012A1 (fr) Benzamides pour le traitement de dégénérescences neurologiques.
ZA9810974B (en) Conjugates useful in the treatment of prostate cancer
ZA200203166B (en) Treatment of cancer.
HK1050533A1 (en) Substituted pyrroles as antiproliferative agents for the treatment of cancer.
FR2785545B3 (fr) Calecon pour le traitement topique de la cellulite
AU7130696A (en) Combination of beta-interferon for the treatment of prostate cancer
ZA979655B (en) Conjugates useful in the treatment of prostate cancer.
FR2686391B3 (fr) Ensemble de robinet.
ES1031709Y (es) Prenda interior.
HK1034979A1 (en) Conjugates useful in the treatment of prostate cancer.